The Alzheimer's Disease and Memory Disorders Center at Rhode Island Hospital
Clinical Trials Program: Currently active or enrolling
| Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A-4 trial) | Phase 3 secondary prevention multicenter trial aimed at treating older individuals at risk for developing Alzheimer’s disease dementia on the basis of having biomarker evidence of amyloid, by decreasing amyloid burden with solanezumab during the preclinical stage and hopefully delay cognitive decline over 3 years. |
| Aducanumab anti-amyloid antibody (EMERGE trial) | Phase 3, multicenter trial to to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment in participants with early AD over 72 weeks. |
| LY-3002813 anti-amyloid antibody (TRAILBLAZER trial) | Phase 2, multicenter trial to assess the efficacy of LY-3002813 in slowing cognitive and functional impairment in participants with early Alzheimer's disease over 78 weeks. |
| BIIB092 anti-tau antibody (TANGO trial) | Phase 2, multicenter trial to assess the efficacy of BIIB092 in slowing cognitive and functional impairment in participants with mild cognitive impairment due to Alzheimer's disease or with mild Alzheimer's disease over 78 weeks. |
| ABBV-8E12 anti-tau antibody (AWARE trial) | Phase 2, multicenter trial to assess the efficacy of ABBV-8E12 in slowing disease progression in people with early Alzheimer's disease and to assess long term efficacy for up to 96 weeks. |
| Troriluzole (T2 PROTECT AD trial) | Phase 2, multicenter trial to determine if troriluzole can protect against, slow down, and potentially improve memory and thinking problems that increase as Alzheimer's disease progresses over 48 weeks. |
| BAN2401 anti-amyloid antibody (CLARITY-AD trial) | Phase 3, multicenter trial to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease as well as the long-term safety and tolerability of BAN240 over 78 weeks. |
| Alzheimer's Disease NeuroImaging Initiative (ADNI-3) | This study is to develop improved brain imaging and biomarker methods in people with Alzheimer's disease, mild cognitive impairment, and normal elderly by acquiring high quality longitudinal data that will be shared with the world wide research community. |
| Trial Ready Cohort for the Prevention of Alzheimer's Disease (TRC-PAD) | This study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. |
For more information about the clinical trials and research donation programs and how you can help, contact Terry Fogerty at (401)606-4664 or email [email protected].